Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Cancer Prevention
•
Breast Cancer, Non-metastatic
How do you counsel patients about hormonal contraception in patients with high risk benign breast pathology (i.e. LCIS, ADH, ALH) who would quality for chemoprevention?
Related Questions
How do you approach the decision for adjuvant chemotherapy in perimenopausal patients with ER+ breast cancer?
How do you manage steroid refractory pneumonitis due to docetaxel or trastuzumab?
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
How would you approach treatment for local chest wall recurrence while on Anastrozole for a postmenopausal woman with ER+ IDC s/p mastectomy?
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
What are your top takeaways from ESMO 2023?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
How would you discuss the prognosis of HR-positive early breast cancer in an elderly >90 patient who elects against surgery in favor of endocrine treatment only?
Do you approach systemic therapy any differently for patients with locally advanced relapses of TNBC with metaplastic squamous differentiation, as opposed to patients with TNBC?
Would you offer OFS 5 years out from diagnosis in a young patient whose menses have returned with previously treated IDC?
